Replies to post #170977 on Biotech Values

[biomaven0]

>>all this favorable data

We don't in fact have that much new relevant data - the key for the FDA is what the event rate is in 3rd-line patients. The dose analysis should help.

I really can't predict what the FDA timing will be. I still expect the drug will be back on the market with a narrower label and a REMS of some sort.

Peter